For years, venture capital board seats have been treated as a routine part of backing ambitious startups. The Justice Department’s inquiry into Andreessen Horowitz suggests that convention may be colliding with an AI industry where yesterday’s adjacent companies can become today’s rivals.

The scrutiny centers on a16z’s representation at Databricks and Fivetran. Bloomberg reported that a “nearly year-old investigation” is examining whether the firm’s investment partners are “improperly serving on the boards of competing artificial intelligence companies.” Ben Horowitz sits on Databricks’ board, while Martin Casado moved from dbt Labs’ board to Fivetran’s after Fivetran acquired dbt Labs.¹

That timeline matters. The arrangement was not necessarily controversial when the investments and board appointments were made: the companies did not begin as clear-cut head-to-head competitors. But the growth of AI products has blurred those boundaries, giving regulators a reason to ask whether one investor’s access to competing companies could create conflicts—or curb competition.

TechCrunch described the inquiry as a revival of a “112-year-old antitrust law that’s rarely used against VCs,” turning what had looked like ordinary portfolio oversight into a broader test for the industry.² Its central question is less about a single pair of board seats than about what happens when a venture firm’s portfolio companies expand into one another’s markets.

A separate report also identified Andreessen Horowitz as the focus of a DOJ probe over board directors, underscoring that the investigation has become a visible pressure point for the firm.³

The competing interpretations are stark. For investors, overlapping board roles can be part of helping young companies scale. For antitrust enforcers, those same roles may look different once AI-driven expansion makes the companies competitors. The DOJ’s eventual view could force VCs to rethink how long they hold—and how they police—board seats across a rapidly converging portfolio.